TCM
ACET icon

Tekla Capital Management’s Adicet Bio ACET Stock Holding History

Tekla Capital Management’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$98K Hold
2,521
– – ﹤0.01% 158
2023
Q1 		$232K Hold
2,521
– – 0.01% 164
2022
Q4 		$361K Hold
2,521
– – 0.01% 153
2022
Q3 		$573K Sell
2,521
-1,437
-36% -$365K 0.02% 145
2022
Q2 		$925K Hold
3,958
– – 0.04% 136
2022
Q1 		$1.26M Hold
3,958
– – 0.04% 138
2021
Q4 		$1.11M Buy
+3,958
New +$679K 0.04% 145

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Tekla Capital Management's ACET Position: Q2 2023 in Review

Tekla Capital Management held its Adicet Bio (ACET) position steady in Q2 2023 at 2,521 shares worth $98K. The position accounts for ﹤0.01% of the portfolio, ranked #158.

Tekla Capital Management first reported a position in ACET in Q4 2021 and has held it in 7 quarters since. The position peaked at $1.26M in Q1 2022. 94 funds tracked by Wall St. Rank hold ACET as of Q2 2023.

  • Tekla Capital Management held 2,521 shares of Adicet Bio worth $98K as of Q2 2023.
  • Tekla Capital Management left its Adicet Bio share count unchanged in Q2 2023.
  • Adicet Bio made up ﹤0.01% of Tekla Capital Management's portfolio in Q2 2023, its #158 holding.
  • Tekla Capital Management first reported a position in Adicet Bio in Q4 2021 and has held it in 7 quarters since.
  • Tekla Capital Management's Adicet Bio position peaked at $1.26M in Q1 2022.
  • 94 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.